Convexity Meningioma — Symptoms, Diagnosis, Treatment, and Prognosis

Most readers benefit from reviewing this Quick Summary together with the sections on Symptoms of Convexity Meningioma, Diagnosis, Surgical Treatment, Radiation Therapy, and Treatment Decision-Making. Later sections provide more detailed explanations intended for patients seeking a deeper understanding before important treatment decisions are made.

What Is a Convexity Meningioma

A convexity meningioma is a tumor that arises from the dura mater covering the outer surface of the brain, known as the cerebral convexity. These tumors develop outside the brain tissue and typically grow toward the brain, compressing the underlying cerebral cortex.

Most meningiomas arise from specialized cells located within the arachnoid layer, often referred to as arachnoid cap cells. When genetic changes occur in these cells, they may begin to multiply abnormally and gradually form a tumor. Unlike tumors that originate inside the brain tissue, convexity meningiomas grow outside the brain, attached to the dura along the outer brain surface beneath the skull. As the tumor enlarges, it usually compresses the surrounding brain tissue without direct brain invasion. Because of this growth pattern, most convexity meningiomas remain well-defined masses that can usually be surgically separated from the brain.

Epidemiological studies show that meningiomas represent approximately 35–41% of all primary intracranial tumors in adults, making them the most common primary brain tumor. Convexity meningiomas account for approximately 20–25% of intracranial meningiomas. Small incidental meningiomas may be present in approximately 0.5–1% of the general population, based on autopsy and imaging studies. Most of them never cause symptoms or require treatment.

Meningiomas are also rare in children, representing less than 2% of all pediatric brain tumors. When they occur in younger patients, they are more frequently associated with genetic syndromes such as neurofibromatosis type 2 (NF2).

Image: A convexity meningioma growing from the coverings of the brain (meninges, dura mater) and compressing surrounding parts of the brain, without infiltrating them.

You can read more about other brain tumors on our Brain Tumors page.

Biological Classification of Convexity Meningioma

The biological behavior of convexity meningiomas is determined through histopathological analysis using the World Health Organization (WHO) classification.

Three main categories are recognized:
• WHO grade I — benign meningioma. This is the most common form, representing roughly 80–85% of meningiomas. These tumors typically grow slowly and often remain stable for long periods. When completely removed surgically, the chance of recurrence is relatively low.
• WHO grade II — atypical meningioma. Atypical meningiomas account for approximately 10–15% of cases in surgical series of meningiomas. These tumors show increased cellular activity and a higher likelihood of recurrence after surgery. After complete tumor removal, some patients may be managed with MRI follow-up rather than immediate radiation therapy.
• WHO grade III — malignant (anaplastic) meningioma. These tumors are rare, representing roughly 1–3% of cases in surgical series of meningiomas. They grow more aggressively, recur more frequently, and usually require combined treatment with surgery and radiation therapy.

Although histological grade is important, clinical outcome also depends strongly on the exact cortical location of the tumor and the possibility of complete surgical removal.

Genetic and Biological Causes of Convexity Meningioma

Most convexity meningiomas arise from sporadic genetic mutations that occur during life rather than inherited genetic disorders. At the molecular level, tumor development usually results from two main biological mechanisms:

• inactivation of tumor suppressor genes, which normally prevent uncontrolled cell growth
• activation of oncogenic signaling pathways, which stimulate cell proliferation

The most frequently involved gene is NF2, located on chromosome 22. Loss of function of this gene disrupts normal cell growth control and allows tumor formation. Other molecular alterations identified in meningiomas include mutations involving genes such as TRAF7, AKT1, SMO, and KLF4, while additional less common alterations may involve genes such as PIK3CA or TERT.

These molecular differences partly explain why tumors in different anatomical regions may behave differently.

The only clearly established environmental risk factor is exposure to ionizing radiation, particularly during childhood.

Meningiomas occur approximately two to three times more frequently in women than in men, suggesting that hormonal influences may play a role in tumor development and growth.

Although most meningiomas arise sporadically, a small proportion occur in the context of inherited genetic syndromes. The best known example is neurofibromatosis type 2 (NF2), a hereditary condition caused by mutations of the NF2 gene on chromosome 22. Patients with NF2 frequently develop multiple meningiomas, a condition referred to as meningiomatosis, in which several tumors arise in different intracranial and spinal locations. Multiple meningiomas may also appear sporadically without a hereditary syndrome, but they are particularly characteristic of NF2. In addition, meningiomas may occur in association with other rare genetic disorders such as schwannomatosis or Cowden syndrome, although these situations are much less common. Overall, hereditary syndromes account for only a small minority of meningioma cases.

Location of Convexity Meningiomas

Convexity meningiomas arise on the outer surface of the brain beneath the skull. They develop from the dura covering the cerebral convexity rather than from deep skull base structures.

They account for approximately 20–25% of intracranial meningiomas, making them one of the most common meningioma locations.

The exact cortical region involved is extremely important because it determines both the symptoms and the complexity of surgical treatment.

Convexity meningiomas may arise over different functional parts of the cerebral hemispheres. Tumors over the frontal convexity may cause headaches, behavioral change, or weakness, whereas tumors over the parietal convexity may produce sensory symptoms, spatial difficulties, or seizures.

Multiple Convexity Meningiomas (Meningiomatosis)

Most patients develop a single meningioma, but approximately 5–10% of patients present with multiple tumors. This condition is referred to as multiple meningiomas or meningiomatosis.

Multiple meningiomas may occur sporadically, but they are particularly associated with neurofibromatosis type 2, in which patients may develop numerous tumors along the meninges.

Management of multiple meningiomas is individualized. In many cases only the symptomatic or growing tumors are treated, while the remaining lesions are monitored with periodic imaging.

How Convexity Meningiomas Grow and Affect the Brain

Convexity meningiomas usually grow slowly over many years. Because they arise outside the brain tissue, they primarily damage the brain through compression rather than invasion. As the tumor enlarges, it gradually presses on adjacent cortical brain structures. This pressure interferes with normal neuronal activity and may lead to neurological deficits.

Another important mechanism is peritumoral brain edema, a form of swelling in the surrounding brain tissue caused by leakage of fluid from nearby blood vessels. This swelling increases intracranial pressure and often worsens symptoms.

Together with the tumor itself, this edema can produce a mass effect, meaning that the expanding lesion compresses and displaces normal brain structures. Because the skull is a rigid, closed cavity with very limited space for expansion, increasing pressure may force parts of the brain to shift from their normal position. In severe cases, brain tissue can be pushed through natural openings within the skull, a condition known as brain herniation. Herniation represents a dangerous stage of mass effect in which displaced brain structures may compress vital centers in the brainstem responsible for consciousness, breathing, and circulation.

Large tumors may also compress nearby arteries or veins, disrupting normal blood circulation in the brain. In some cases, very large lesions with marked edema may contribute to increased intracranial pressure and secondary neurological deterioration.

Even though most convexity meningiomas do not invade brain tissue, prolonged compression may still cause permanent neurological damage if the tumor becomes very large.

Studies following patients with untreated meningiomas have shown that a substantial proportion of tumors remain stable for long periods. Approximately 30–35% of meningiomas show no measurable growth during long-term imaging follow-up. Among tumors that do grow, the increase in size is usually slow and gradual, often measured in millimeters per year rather than rapid expansion.

Symptoms of Convexity Meningioma

The symptoms caused by convexity meningiomas depend largely on their exact anatomical location, tumor size, surrounding edema, and the cortical region involved.

Convexity meningiomas often produce seizures because they irritate the surface of the brain. Patients may also develop progressive weakness or numbness affecting the arm and/or leg on the opposite side of the body.

Tumors located over the motor cortex may produce progressive weakness, clumsiness, or loss of fine motor control on the opposite side of the body. Tumors over the sensory cortex may cause numbness, altered sensation, or sensory neglect. Frontal convexity tumors may lead to headaches, slowed thinking, reduced concentration, personality changes, or behavioral changes when significant edema affects the frontal lobes. Parietal convexity tumors may produce sensory symptoms, difficulties with spatial orientation, or focal seizures depending on the dominant or nondominant hemisphere involved.

Headache is common, particularly in larger tumors associated with significant edema or raised intracranial pressure. Headache in patients with small meningiomas does not necessarily mean that the tumor is the cause. Many patients have common primary headache disorders such as tension-type headache, migraine, or cervicogenic headache, which are frequent in the general population and may occur independently of the tumor. For this reason, the type of headache should be carefully evaluated and defined before attributing the symptoms to the meningioma, and the presence of headache alone is usually not a sufficient reason to recommend immediate surgical removal of a small, otherwise asymptomatic tumor.

Some patients remain entirely asymptomatic, especially when the tumor is discovered incidentally on MRI or CT performed for unrelated reasons.

Image: Functional centers in the brain cortex

Diagnosis of Convexity Meningioma

The most important diagnostic test is MRI of the brain with contrast.

During this examination, the patient lies inside the MRI scanner while magnetic fields generate highly detailed images of the brain. A contrast agent injected through a vein highlights tumor tissue.

MRI allows physicians to determine:

• tumor size
• precise location
• relationship to the brain surface and nearby vessels
• presence of surrounding brain edema

Convexity meningiomas typically appear as well-defined tumors located outside the brain tissue, attached to the dura along the cerebral convexity, often accompanied by a characteristic imaging feature known as the dural tail.

The final diagnosis is confirmed through histopathological analysis after surgery or biopsy.

Image: Brain MRI showing a bright convexity meningioma (image after applying contrast) in the right parietal region, causing a significant mass effect (compression) on the brain due to its size and surrounding brain edema. In the inferior extension of the tumor, there is a bright dural thickening called the ‘dural tail sign’.

However, several other conditions may produce similar MRI findings and must be considered in the differential diagnosis.

These include:

• dural metastases, which may mimic meningiomas when metastatic cancer spreads to the meninges
• hemangiopericytoma (solitary fibrous tumor), a rare dural tumor that can appear very similar radiologically but behaves more aggressively
• lymphoma involving the dura
• other dural-based lesions that may resemble convexity meningioma on imaging

Because imaging findings may overlap, the final diagnosis is often confirmed by histopathological examination of the tumor after surgical removal or biopsy.

Although MRI is the main imaging method used to diagnose convexity meningiomas, other techniques may occasionally provide additional information. CT scans are particularly useful for evaluating changes in the skull bone, such as hyperostosis or calcification within the tumor. In selected cases, vascular imaging such as CT angiography or MR angiography may also be performed to assess the relationship of the tumor to major cortical veins or arteries when surgical planning requires more detailed evaluation. Conventional catheter angiography (DSA) is now rarely required and is mainly performed when preoperative tumor embolization is being considered.

Monitoring Without Treatment: When Convexity Meningiomas Are Only Observed

Not all convexity meningiomas require immediate treatment.

Approximately 30–50% of newly diagnosed meningiomas are initially managed with active surveillance rather than immediate surgery. Among incidentally discovered tumors, however, observation without surgery is chosen in the majority of patients, often around 60–80%, particularly when the tumor is small and not causing symptoms.

Monitoring is usually recommended when:
• the tumor causes no neurological symptoms, especially if it is small
• imaging shows little or no growth over time
• the tumor is not compressing important cortical brain structures
• there is little or no surrounding brain edema
• the patient is elderly or has serious medical conditions

On imaging studies, meningiomas that are partially or extensively calcified often represent tumors with long-standing slow growth, and this finding may further support a decision for observation rather than immediate surgery. Follow-up generally involves MRI examinations every 6–12 months initially.

Symptomatic Treatment for Convexity Meningioma

Medications are often used to control complications caused by the tumor.

• Brain swelling (edema) is commonly treated with corticosteroids, most often dexamethasone, which reduces edema in the surrounding brain tissue.
• Seizures are treated with antiepileptic medications, such as levetiracetam or other modern antiseizure drugs.

These medications stabilize the patient but do not eliminate the tumor itself.

Convexity Meningioma and Epilepsy

Seizures may sometimes be the first symptom of a convexity meningioma, particularly when the tumor is located near the cerebral cortex.

However, it is important to understand that not every seizure in a patient with a convexity meningioma is necessarily caused by the tumor. Epilepsy is relatively common in the general population, and the coexistence of a small incidental meningioma does not automatically mean that the tumor is responsible for the seizures.

For this reason, physicians must carefully evaluate whether the tumor is actually the source of epileptic activity. This assessment usually includes:

• analysis of tumor location relative to the cerebral cortex
• evaluation of peritumoral brain edema
• correlation between EEG findings and the tumor region
• consideration of other possible causes of epilepsy

When seizures are clearly related to the tumor, surgical removal of the convexity meningioma often significantly reduces seizure frequency, and in some patients seizures may stop completely.

Antiepileptic medications are usually used to control seizures before and for some period after surgery.

Surgical Treatment of Convexity Meningioma

Surgery remains the primary treatment for symptomatic or progressively growing convexity meningiomas. The procedure is performed through a craniotomy, which involves temporarily removing a portion of the skull to access the tumor.

In most cases the operation proceeds through several stages:

• Skin incision and craniotomy
The scalp is opened using a carefully planned incision. Depending on the location of the tumor, the incision may be linear, curved, or horseshoe-shaped. Whenever possible, it is placed within the hairline for cosmetic reasons. In most modern neurosurgical procedures the hair does not need to be completely shaved. A small bone flap is then created to expose the dura mater covering the tumor.

• Opening of the dura
The dura mater is carefully opened to expose the tumor and the surrounding brain structures. The dura is circumferentially incised around the tumor attachment, which helps interrupt a major portion of the arterial blood supply entering the tumor and reduce intraoperative bleeding during subsequent tumor removal. Smaller feeding vessels may also arise from cortical (brain) arteries at the tumor–brain interface, which must be carefully preserved to avoid injury to the surrounding brain tissue.

• Internal tumor debulking
The tumor is then reduced from the inside, most often using an ultrasonic aspirator (CUSA). This internal debulking decreases tumor volume and pressure, making subsequent dissection from the surrounding brain, cortical vessels, and adjacent tissues safer.

• Microsurgical dissection
The tumor is gradually separated from the surrounding brain tissue and cortical vessels under high magnification using the neurosurgical microscope.

• Tumor removal
After internal decompression of the tumor, the remaining peripheral tumor remnants are carefully separated from the surrounding brain tissue and cortical vessels and then removed piece by piece.

• Treatment of the dural attachment
Because convexity meningiomas arise from the dura, the involved portion of the dura is removed together with the tumor to reduce the risk of recurrence. When complete removal is not safe, the dural base may be coagulated. If a segment of dura is removed, the defect is typically reconstructed using a dural graft to restore a watertight barrier around the brain. This graft may be created from the patient’s own tissue, such as periosteum elevated from the skull during the operation or muscle fascia. The dura can also be replaced by biocompatible artificial dural substitutes specifically designed for neurosurgical reconstruction.

• Removal of infiltrated bone (when present)
Some convexity meningiomas cause thickening or infiltration of the adjacent skull bone (hyperostosis). In such cases the abnormal bone may be drilled away, and occasionally a larger bone segment must be removed and at the same surgery or later reconstructed with a cranioplasty.

• Dural reconstruction and closure
After tumor removal the dura is reconstructed using a dural graft if necessary. The bone flap is replaced, or reconstructed if bone was removed, and the scalp is closed.

Image: The image illustrates a craniotomy. Both the skin incision and the skull opening are performed within the hair-bearing area of the scalp. The dura is opened to expose the tumor or the brain as part of the surgical approach to the tumor. After the procedure, the bone flap is secured and the scalp is reconstructed, ensuring no cosmetic defect remains after healing.

Image: Stages of surgical removal of a meningioma. After craniotomy and opening of the dura, image (a) shows the dark brown meningioma. Image (b) illustrates its separation from the brain, blood vessels, and other normal tissues, followed by its piecemeal reduction. Image (c) shows the removal of the remaining peripheral parts of the meningioma. Image (d) shows the condition after the meningioma has been completely removed.

Modern Surgical Technologies for Convexity Meningioma

Modern neurosurgery employs several technologies to increase precision and safety.

• Neuronavigation systems function as intraoperative GPS, allowing the surgeon to navigate within the skull with millimeter accuracy.
• Ultrasonic aspirators (CUSA) fragment and aspirate tumor tissue while preserving surrounding blood vessels and brain tissue.
• Intraoperative neurophysiological monitoring allows continuous monitoring of motor or sensory pathway function during surgery when the tumor is close to eloquent cortical areas, helping avoid surgical damage to important functional regions.

These technologies significantly reduce the risk of neurological injury.

Read more about potential complications following craniotomy and open brain surgery on this page.

In selected cases, surgeons may perform preoperative embolization before surgical removal of a convexity meningioma. This procedure involves inserting a catheter into arteries supplying the tumor and injecting materials that reduce blood flow to the tumor in order to decrease intraoperative bleeding. Embolization is mainly considered for large, highly vascular meningiomas supplied by branches of the external carotid artery. Today it is used in a relatively small proportion of cases because the procedure itself may carry risks such as stroke or unintended embolization of normal vessels, and advances in modern microsurgical techniques have reduced the need for routine embolization.

Extent of Convexity Meningioma Removal — Simpson Classification

The completeness of tumor removal is classified using the Simpson grading system.

• Simpson Grade I — complete removal of the tumor and its dural attachment
– recurrence risk approximately 5–10% over long-term follow-up
– probability of needing another intervention ~3–5%

• Simpson Grade II — tumor removed, dural attachment coagulated
– recurrence risk approximately 10–20%
– probability of further treatment ~5–10%

• Simpson Grade III — tumor removed but dura left intact
– recurrence risk approximately 20–30%
– probability of additional treatment ~10–20%

• Simpson Grade IV — subtotal removal
– recurrence risk approximately 40–60%
– additional treatment (surgery or radiotherapy) often required in 30–50%

• Simpson Grade V — biopsy or decompression only
– tumor progression expected in most patients (>80–90%)
– further definitive treatment usually necessary

The Simpson grade strongly influences the likelihood of tumor recurrence.

Because convexity meningiomas are often more accessible than deep skull base tumors, complete removal including the dural attachment is more frequently achievable, which is one of the reasons why their long-term prognosis is often favorable.

Radiation Therapy for Convexity Meningioma

Radiation therapy is used when complete surgical removal is not possible, when tumors recur, or when a small residual tumor remains after surgery. It may also be considered for small convexity meningiomas that demonstrate clear growth during imaging follow-up, particularly when surgery carries increased risk or in situations where the patient prefers a non-surgical treatment option after discussion of the risks and benefits.

Typical radiation doses for meningiomas are:

• 12–14 Gy delivered in a single session in stereotactic radiosurgery
• less commonly, about 50–54 Gy in conventionally fractionated radiotherapy

Radiosurgery is generally most suitable for tumors smaller than about 2.5–3 cm that do not cause significant compression of the brain.

Radiation therapy can effectively stop tumor growth in many patients. Modern radiation techniques provide long-term tumor control in approximately 85–95% of benign meningiomas, especially when small residual or recurrent tumors are treated with stereotactic radiosurgery.

Even in convexity meningiomas, radiation therapy is not appropriate for all tumors. Large lesions with marked edema, significant mass effect, or symptomatic cortical compression are usually better managed surgically because decompression is required.

The final treatment decision is usually made after careful evaluation of tumor size, exact cortical location, patient age, symptoms, surrounding edema, and overall medical condition.

Recurrence of Convexity Meningioma

Recurrence of convexity meningioma is uncommon after complete removal, but it may still occur depending on the WHO tumor grade and the extent of surgical resection.

After complete removal of benign (WHO Grade I) meningiomas, long-term recurrence rates are usually around 5–10%.
When subtotal removal is performed, recurrence rates are higher.

Atypical (WHO Grade II) meningiomas recur more frequently, while malignant (WHO Grade III) tumors have the highest recurrence risk and usually require additional radiotherapy.

Because recurrence may appear many years after treatment, long-term MRI follow-up is essential.

➡ Detailed explanation of recurrence patterns, risk factors, and treatment options is explained here:
Meningioma Recurrence — Causes, Risk, and Treatment

Treatment Strategy by Tumor Grade in Convexity Meningioma

Management also depends strongly on the WHO tumor grade.

• WHO grade I meningiomas. After complete surgical removal, most patients require only periodic MRI follow-up. If the tumor recurs during follow-up, management may include continued observation, repeat surgery, or stereotactic radiosurgery, depending on the rate of growth and clinical symptoms.
• WHO grade II (atypical) meningiomas. These tumors recur more frequently. Postoperative radiotherapy is often recommended, particularly after incomplete tumor removal, although some patients may be managed with close MRI follow-up after complete resection.
• WHO grade III (malignant) meningiomas. These aggressive tumors typically require postoperative radiotherapy regardless of the completeness of surgical removal, together with close imaging follow-up.

Long-Term Monitoring of Convexity Meningioma

Because convexity meningiomas may recur many years after treatment, long-term follow-up is essential.

Typical surveillance includes:

• annual MRI for several years after treatment
• longer imaging intervals if the tumor remains stable

Early detection of recurrence allows treatment before significant neurological damage develops.

Experimental and Targeted Therapies for Convexity Meningioma

Experimental and Targeted Therapies for Convexity Meningioma
Several medications have been investigated for recurrent or progressive meningiomas when surgery and radiotherapy are no longer sufficient. These include bevacizumab, which targets tumor blood vessel growth, as well as treatments acting on molecular pathways involved in tumor development, including AKT and SMO inhibitors. Somatostatin-receptor-based therapies such as octreotide and combinations including everolimus have also been studied.

In recent years, interest has increased in targeted treatment approaches for meningiomas with specific molecular alterations such as NF2, AKT1, or SMO mutations. However, most of these therapies remain under clinical investigation, and current evidence is still limited. At present, there is no established drug therapy that reliably controls most convexity meningiomas, which is why surgery and radiotherapy remain the main treatment options for the majority of patients.

When Expert Opinions May Differ in Convexity Meningioma

Differences in specialist recommendations do not necessarily indicate that one opinion is wrong. In convexity meningioma management, treatment strategy may vary depending on how a physician weighs tumor size, exact cortical location, documented growth, presence of brain edema, neurological symptoms, and patient age, as well as the balance between observation, surgery, and radiation therapy.

In many patients, the diagnosis is clear, but the decision about treatment is not. When a meningioma is discovered, especially incidentally, different specialists may recommend MRI monitoring, early surgery, or radiation therapy, even when reviewing the same imaging findings.

These differences arise because treatment decisions depend on how risk is interpreted. Some specialists place greater emphasis on preventing future tumor growth and neurological deterioration, while others prioritize avoiding unnecessary intervention in tumors that may remain stable for years. The same tumor may therefore be managed differently depending on whether the focus is on long-term tumor control or immediate neurological safety.

Uncertainty is particularly common in situations where the tumor is small but located near functionally important cortex, shows minimal or borderline growth, or produces mild or nonspecific symptoms. In such cases, there is often no single universally correct strategy, but rather several acceptable approaches based on clinical judgment and experience.

Because of this, patients are frequently given different recommendations regarding whether to observe or treat, when to intervene, and which treatment modality to choose. Careful analysis of imaging findings together with clinical context usually allows these differences to be explained and helps define the most appropriate strategy for the individual patient.

Observation vs. Early Surgery in Convexity Meningioma

One of the most common differences in opinion occurs when a convexity meningioma is discovered incidentally on MRI and the patient has no symptoms. Some specialists recommend active surveillance, particularly when the tumor is small and shows no signs of growth. Others may recommend early surgery, especially if the tumor is located over an important cortical region where future growth could threaten neurological function. Both approaches may be appropriate depending on the individual clinical situation.

Differences in Surgical Strategy for Convexity Meningioma

Even when surgery is recommended, surgeons may disagree about the optimal surgical strategy. In some cases a surgeon may aim for complete removal including the dural attachment, while another may prefer a more conservative removal if the tumor lies close to important cortical veins or eloquent brain tissue.

Surgery vs. Radiation Therapy in Convexity Meningioma

Another area where opinions may differ involves the use of radiation therapy. Some specialists recommend surgical removal first, followed by radiation only if residual tumor remains. Others may recommend primary stereotactic radiosurgery, particularly for small tumors without significant mass effect. Decisions between surgery and radiation therapy may also depend on tumor size, location, growth rate, proximity to important functional cortical regions, and the expected surgical risk for the individual patient.

Because treatment decisions depend on many individual variables, careful review of MRI images and clinical history often allows specialists to explain why different recommendations may exist and which option is most appropriate for a specific patient.

How Convexity Meningioma Prognosis Depends on Location, Grade, and Extent of Removal

The prognosis of convexity meningioma depends primarily on three major factors: the biological grade of the tumor, its exact anatomical location, and the extent to which it can be safely removed.

In general, WHO Grade I meningiomas have the most favorable prognosis. They usually grow slowly, and when they are completely removed together with their dural attachment, long-term tumor control is often excellent. By contrast, atypical and malignant meningiomas have a higher risk of recurrence, even after apparently complete surgery, and therefore usually require closer follow-up and often additional radiation therapy.

Tumor location is equally important. Convexity meningiomas are often associated with a better surgical prognosis because they can usually be approached more directly and separated more safely from surrounding structures than many deep or skull base meningiomas. However, the exact cortical area remains highly relevant. Tumors located over eloquent motor or sensory cortex, or near important cortical veins, may still require the surgeon to choose between more radical removal and preservation of neurological function.

For this reason, the extent of tumor removal strongly influences long-term outcome. The smaller the amount of residual tumor left behind, the lower the probability of recurrence. However, in modern neurosurgery, the best result does not always mean the most aggressive resection. In some patients, intentionally leaving a very small tumor remnant densely adherent to critical cortical vessels or eloquent brain tissue may provide a better overall outcome than attempting complete removal at the cost of permanent neurological damage.

In practical terms, prognosis is best in patients with benign convexity meningiomas located in surgically favorable regions and removed completely. It is generally less favorable in higher-grade tumors and in cases where only subtotal removal is possible because of the risk to important functional brain structures.

Can a Convexity Meningioma Become Life-Threatening?

Yes, a convexity meningioma can become life-threatening, although this is not the usual course in most patients.

Most convexity meningiomas are slow-growing tumors, and many remain stable for years without causing major neurological problems. However, if the tumor becomes large enough, it may produce severe pressure on the brain, significant surrounding edema, progressive cortical dysfunction, marked intracranial pressure elevation, or brain herniation. In such situations, the danger does not arise only from the biological nature of the tumor itself, but from its mass effect on vital brain structures.

A convexity meningioma may therefore become life-threatening when it causes marked intracranial pressure elevation, brain herniation, repeated seizures with progressive neurological deterioration, or severe mass effect on the brain. This risk is higher in large tumors, tumors associated with extensive edema, and in more aggressive histological forms such as atypical or malignant meningioma.

For this reason, even though convexity meningiomas are often described as benign tumors, they should never be considered harmless solely on the basis of histological grade. Their real clinical significance depends on tumor size, exact cortical location, rate of growth, and the effect they produce on surrounding brain structures.

Frequently Asked Questions About Convexity Meningioma